<DOC>
	<DOCNO>NCT01723254</DOCNO>
	<brief_summary>The purpose study assess safety tolerability different dose PF-06444753 PF-06444752 subject allergic rhinitis .</brief_summary>
	<brief_title>A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Healthy , males female nonchild bear potential , 18 55 year , inclusive , Intermittent persistent allergic rhinitis associate perennial seasonal allergen reactivity screen determine positive specific IgE level â‰¥1 KU/L least one follow common allergen : dust mite ( Dermatophagoides farinae Dermatophagoides pteronyssinus ) , cat , dog , mold ( Alternaria ) , Bermuda grass , common ragweed , oak , Timothy grass elm . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic disease may compromise ability safely participate study . Evidence history clinically significant pulmonary disease ( include allergic nonallergic asthma , chronic obstructive pulmonary disease [ COPD ] , cystic fibrosis , bronchiectasis , chronic bronchitis , emphysema , tuberculosis , pulmonary fibrosis , pulmonary hypertension , others ) . Evidence history clinically significant autoimmune disease ( include rheumatoid arthritis , systemic lupus erythematosus , ulcerative colitis , others ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Vaccines</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Allergic Rhinitis</keyword>
</DOC>